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LETTERS TO THE EDITOR
Surgery for Atrial Septal Defect
Attie et al. (1) are to be congratulated for their ambitious
randomized study of surgery for secundum atrial septal defect
(ASD) in patients over age 40. I believe, however, that their results
do not support their recommendation for surgery in this patient
group.
The only end point that was significantly less frequent in the
surgical group than in the medical group was recurrent pneumonia.
This single component of the composite end point accounted for
three-quarters of the difference between the two groups. There was
no difference between the two groups with respect to heart failure,
pulmonary embolism, peripheral embolism, stroke or total mor-
tality (the authors’ attempt to demonstrate a difference in mortality
by means of complex statistical manipulation notwithstanding).
According to the study, the net gain from the performance of 232
operations for the correction of ASD in patients over age 40 would
be the prevention of approximately 18 cases of pneumonia. In my
opinion such a benefit is hardly worth the cost and suffering the
surgery would cause.
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REPLY
We thank Dr. Bassan very much for his interest about our recent
article concerning surgery for atrial septal defect (ASD) in adults
(1). Our explanation follows.
A compound index is a common strategy recently used for
developing some clinical trials in which the sample size for a
specific “end point” is either not possible or very difficult to obtain
(2). When the sample size is calculated for a compound index, and
it is defined as the primary “end point,” the analysis at the
conclusion of the study should be directed to this “end point” as a
“package” (2,3). Of course, the curiosity to see what happened in
the compound index is unavoidable, but caution needs to be
considered in the interpretation of the results. The way that Dr.
Bassan analyzed the data, we can see that sudden death was almost
significant, but the small number of cases probably did not permit
this conclusion. The high incidence of pneumonia was certainly
unexpected. We do not have a clear explanation for this feature;
however, pulmonary infection was responsible for 28.7% of the
total mortality. Recurrent pneumonia is a difficult diagnosis to be
easily differentiated from pulmonary infarct in these types of
patients. We believe that the pulmonary infarct was probably
underestimated. Our study is the first randomized clinical trial
published about this specific topic, and no complex statistical
manipulation was done (4,5), because the data are the data!
Fause Attie, MD
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Toward a Redefinition of Ischemic
Cardiomyopathy: Is It an Indivisible Entity?
We read with great interest the article by Felker et al. (1) in which
the investigators raised an important question regarding definitions
of ischemic cardiomyopathy (CMP). Based on prognostic differ-
ences, the researchers proposed a new definition of ischemic
cardiomyopathy that reclassifies cases with single-vessel disease as
nonischemic patients.
However, the magnitude of this problem seems considerably
deeper. Conventionally, the pathogenesis of ischemic CMP is
described as sequelae of single or recurrent myocardial infarctions
(MIs), with loss of functioning myocytes, development of fibrosis
and subsequent left ventricular (LV) dysfunction and remodeling.
In contrast, in 1989 Atkinson and Virmani (2) described conges-
tive heart failure due to severe coronary artery disease (CAD)
without MI in 26% of consecutive necropsies with ischemic CMP.
Its pathogenesis in absence of MI was unclear at that time. They
presumed that although this type of coronary CMP may comprise
a subset of ischemic CMP, it may also represent idiopathic-dilated
CMP with coincidental CAD.
Recent investigations have elucidated the pathogenesis of isch-
emic CMP in absence of MI, suggesting that LV function
impairment is related to progression of CAD and does not require
a distinct coronary event, such as MI with enzymatic elevation (3).
Hibernation subsequent to severe CAD represents a precarious
balance between perfusion and tissue viability that cannot be
maintained indefinitely; small but multiple foci of myocardial
necrosis will ultimately occur if blood flow is not increased (4). At
onset of heart failure, myocyte apoptosis occurs (5) contributing to
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the progression of ventricular dysfunction. In patients with severe
CAD, production and release of endothelin, angiotensin II and
activation of neurohormonal systems lead to direct stimulation of
interstitial fibrosis, contributing to the pathophysiology of heart
failure (6,7).
Thus, two distinct types of ischemic CMP could be separated:
ischemic post-MI CMP and ischemic non–post-MI CMP. These
entities have dissimilar prevalence, incidence, natural history and
could require a dissimilar therapeutic approach.
Obviously, the majority of ischemic non–post-MI CMP is
found among patients with severe CAD, LV dysfunction and
congestive heart failure in absence of history of MI. Unfortunately,
Felker et al. (1) did not report the proportion of patients with
ischemic CMP but without history of MI in their population. It
would be of interest to disclose these data.
The main pitfall in the differential diagnosis between ischemic
post-MI and non–post-MI cardiomyopathies in the clinical setting
is related to cases with silent MI in the past. For clinical research
purposes, we propose that patients without a history of MI with
severe diffuse CAD on coronary angiography and significant global
LV dysfunction in absence of regional wall motion abnormalities
and/or scars on echocardiography should be considered as bearing
ischemic non–post-MI CMP. The recognition of this entity as a
different type of ischemic CMP is important for clinical trials and
population-based studies aiming to determinate the prevalence,
natural history and optimal therapeutic strategies for patients with
ischemic non–post-MI CMP.
Alexander Tenenbaum, MD, PhD
Enrique Z. Fisman, MD
Michael Motro, MD
Cardiac Rehabilitation Institute
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REPLY
We appreciate the interest of Drs. Tenenbaum, Fisman and Motro
in our study (1). We agree that there are likely to be important
subsets within the group of patients with ischemic cardiomyopathy
(CMP). As they point out, the characteristics and prognosis of
patients with heart failure as the result of myocardial infarction
(MI) may be different from patients with ischemic CMP and no
previous MI. We concur with their assertion that patients with
ischemic CMP and no prior MI are more likely to have hibernat-
ing myocardium, leading to progressive neurohormonal activation
and myocyte apoptosis if coronary blood flow is not restored.
In response to their inquiry, we reassessed our data to determine
the proportions of patients in the ischemic etiology group with and
without a history of previous MI. Sixty percent of the patients
classified as ischemic using our criteria had a prior MI. Compared
to patients in the ischemic group without prior MI, the MI group
had a significantly better unadjusted survival (49% vs. 32% at five
years, p  0.001). Survival for both groups was significantly worse
than that of the nonischemic patients (unadjusted survival of 60%
at five years). When history of MI was added to the multivariable
Cox proportional hazards model to adjust for other differences
between the groups, it had a protective effect with a hazard ratio of
0.72 (p  0.001).
One potential explanation for the seemingly paradoxical “pro-
tective effect” of a prior MI in patients with coronary artery disease
(CAD) and heart failure may relate to differences in the type of
coronary disease between the two groups. Even controlling for the
extent of CAD using the number of diseased vessels or the CAD
index cannot completely adjust for differences in the nature of the
CAD (focal vs. diffuse) and the likelihood and completeness of
revascularization. We hypothesize that patients with “ischemic
non–post-MI CMP” would be more likely to have diffuse coronary
disease not readily amenable to traditional revascularization tech-
niques, potentially explaining their worse outcomes. The upcom-
ing STICH trial may shed further light on the efficacy of various
surgical therapies in different subgroups of patients with heart
failure and CAD.
G. Michael Felker, MD
Linda K. Shaw, MS
Christopher M. O’Connor, MD
Duke University Medical Center
Box 31185
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